2. Academic Validation
  3. Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer

Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer

  • Nat Commun. 2024 Mar 27;15(1):2700. doi: 10.1038/s41467-024-46531-1.
Isabel Baroja 1 2,  Nikolaos C Kyriakidis 3,  Georg Halder 4,  Iván M Moya 5 6
Affiliations

Affiliations

  • 1 Cancer Research Group, Faculty of Engineering and Applied Sciences, Universidad de Las Américas, Quito, Ecuador.
  • 2 Faculty of Health Sciences and Medicine, Universidad de Extremadura, Mérida, Spain.
  • 3 Cancer Research Group, Faculty of Health Sciences, Universidad de Las Américas, Quito, Ecuador.
  • 4 VIB Center for Cancer Biology and Department of Oncology, KU Leuven, Leuven, Belgium. [email protected].
  • 5 Cancer Research Group, Faculty of Engineering and Applied Sciences, Universidad de Las Américas, Quito, Ecuador. [email protected].
  • 6 VIB Center for Cancer Biology and Department of Oncology, KU Leuven, Leuven, Belgium. [email protected].
PMID: 38538573 DOI: 10.1038/s41467-024-46531-1
Abstract

Hyperactivation of YAP/TAZ, the Hippo pathway downstream effectors, is common in human Cancer. The requirement of YAP/TAZ for Cancer cell survival in preclinical models, prompted the development of pharmacological inhibitors that suppress their transcriptional activity. However, systemic YAP/TAZ inhibition may sometimes have unpredictable patient outcomes, with limited or even adverse effects because YAP/TAZ action is not simply tumor promoting but also tumor suppressive in some cell types. Here, we review the role of the Hippo pathway in distinct tumor cell populations, discuss the impact of inhibiting Hippo output on tumor growth, and examine current developments in YAP/TAZ inhibitors.

Figures